News
-
Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest
The drug maker Pfizer announced yesterday that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly effective in preventing Covid-19, a promising development as the world…
Read More » -
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020
TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
Read More » -
Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021
The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021. …
Read More » -
Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo
A Joint Conference on thalassaemia by the Egyptian Thalassemia Association (ETA), the Egyptian Society of Hematology & Research (ESHR) and the Thalassaemia International Federation (TIF) will be held on 25-26…
Read More » -
GoCART Coalition: EHA and EBMT Join Forces To Position Europe In The Lead Of The Global Cellular Therapy Field
The European Hematology Association (EHA) and the European Society of Blood and Marrow Transplantation (EBMT) announce a strategic partnership to empower Europe to become a global leader in the cellular…
Read More » -
PK Deficiency Resources Now Available On TIF’s Website
Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…
Read More » -
Cyprus President Anastasiades Welcomed A TIF Delegation
An official meeting with the President of the Republic of Cyprus, Mr. Nicos Anastasiades, was held this morning by a delegation of the Thalassaemia International Federation, headed by the President…
Read More » -
-
Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19. According to Roche, AT-527 blocks the viral RNA polymerase enzyme…
Read More » -
Leave No Patient Behind: A TIF Declaration For Access To Health At The Time of The COVID-19 Pandemic
Download the TIF Declaration HERE
Read More »